SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).
NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RMD, you can request additional information here:...
Covered in this story
Analyst targets on ResMed
- Stifel: at $219 · target $235 by Oct 2027 · Hold via Investing.com
- RBC Capital Markets: at $229 · target $262 by Sep 2027 · Outperform via Investing.com
- KeyBanc Capital Markets: at $240 · target $267 by Aug 2027 · Overweight via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ResMed →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.